Idursulfase
Clinical data
AHFS/Drugs.comMonograph
License data
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
 ☒NcheckY (what is this?)  (verify)

Idursulfase (brand name Elaprase), manufactured by Takeda, is a drug used to treat Hunter syndrome (also called MPS-II).[2] It is a purified form of the lysosomal enzyme iduronate-2-sulfatase and is produced by recombinant DNA technology in a human cell line.

It is one of the most expensive drugs ever produced, costing US$567,412 per patient per year.[3][4][5]

References

  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
  2. ^ Garcia AR, DaCosta JM, Pan J, Muenzer J, Lamsa JC (2007). "Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II". Mol. Genet. Metab. 91 (2): 183–90. doi:10.1016/j.ymgme.2007.03.003. PMID 17459751.
  3. ^ "Drug approved to treat rare but potentially deadly disease". Archived from the original on 2011-02-24. Retrieved 2011-04-29.
  4. ^ Health Care: The World's Most Expensive Drugs, Matthew Herper, Forbes, Feb. 22, 2010
  5. ^ [1], Barbara Kollmeyer, Marketwatch, Fed. 3, 2016

External links


Other alimentary tract and metabolism products (A16)
Categories